Literature DB >> 26160846

Implications for determining the optimal treatment for locally advanced rectal cancer in elderly patients aged 75 years and older.

Jue-feng Wan1, Ji Zhu1, Gui-chao Li1, Wen-jie Sun1, Zhen Zhang1.   

Abstract

Patients were excluded if they were older than 75 years of age in most clinical trials. Thus, the optimal treatment strategies in elderly patients with locally advanced rectal cancer (LARC) are still controversial. We designed our study to specifically evaluate the cancer specific survival of four subgroups of patients according to four different treatment modalities: surgery only, radiation (RT) only, neoadjuvant RT and adjuvant RT by analyzing the Surveillance, Epidemiology, and End Results (SEER)-registered database. The results showed that the 5-year cancer specific survival (CSS) was 52.1% in surgery only, 27.7% in RT only, 70.4% in neoadjuvant RT and 60.4% in adjuvant RT, which had significant difference in univariate log-rank test (P < 0.001) and multivariate Cox regression (P < 0.001). Thus, the neoadjuvant RT and surgery may be the optimal treatment pattern in elderly patients, especially for patients who are medically fit for the operation.

Entities:  

Keywords:  SEER; elderly; optimal; rectal cancer

Mesh:

Year:  2015        PMID: 26160846      PMCID: PMC4745806          DOI: 10.18632/oncotarget.4599

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) is a standard treatment in patients aged 75 years and younger with locally advanced rectal cancer (LARC) [1-5]. Patients were excluded if they were older than 75 years of age in most clinical trials. Elderly patients are more likely to have other concomitant chronic illnesses, which may increase the risk of complications and even death during treatment. Thus, the optimal treatment strategies in elderly patients are still controversial. We designed our study to specifically evaluate the cancer specific survival of four subgroups of patients according to four different treatment modalities: surgery only, radiation (RT) only, neoadjuvant RT and adjuvant RT by analyzing the Surveillance, Epidemiology, and End Results (SEER)-registered database.

RESULTS

Patient characteristics

We identified 4,121 eligible elderly patients with LARC in SEER database during the 8-year study period (between 2004 and 2011), which included 1460 patients in surgery only, 577 patients in RT only, 1498 patients in neoadjuvant RT and 586 patients in adjuvant RT. There were 2077 (50.4%) males and 2044 (49.6%) females. Patient demographics and pathological features are summarized in Table 1. Compared with the decreasing pattern of surgery only and adjuvant RT, the increasing trends of neoadjuvant RT and RT only were observed from 2004 to 2011 (Figure 1).
Table 1

Patient characteristics

VariableTotalSurgery onlyRT onlyNeoadjuvant RTAdjuvant RTP value
n=4,121n=1,460n=577n=1,498n=586
Sex<0.001
 Male207745.8%48.2%55.3%51.4%
 Female204454.2%51.8%44.7%48.6%
Race0.359
 White350485.8%82.3%85.1%85.5%
 Black2655.6%8.5%6.6%6%
 Other3528.6%9.2%8.3%8.5%
Pathological grading<0.001
 Grade I4129%10.9%9.7%12.3%
 Grade II270367.9%62.9%66.9%59%
 Grade III38010%8%8.9%9.2%
 Grade IV651%2.9%1.2%2.6%
 Unknown56112.1%15.3%13.2%16.9%
Histological Type<0.001
 Adenocarcinoma384793.3%97.6%92.3%92%
 Mucinous/Signet ring cell2746.7%2.4%7.7%8%
Figure 1

Patterns of care are illustrated for patients who were diagnosed with rectal cancer from 2004 to 2011 according to treatment modality

RT indicates radiotherapy.

Patterns of care are illustrated for patients who were diagnosed with rectal cancer from 2004 to 2011 according to treatment modality

RT indicates radiotherapy.

Impact of different treatment strategies on survival outcomes in elderly patients with rectal cancer

The 5-year CSS was 52.1% in surgery only, 27.7% in RT only, 70.4% in neoadjuvant RT and 60.4% in adjuvant RT, which had significant difference in univariate log-rank test (P < 0.001) (Figure 2). Besides, mucinous/signet-ring cancer (P = 0.022) was identified as a significant risk factor for poor survival on univariate analysis (Table 2). When multivariate analysis with Cox regression was performed, also only treatment patterns and histological type of tumor were the two prognostic factors (Table 2).
Figure 2

Survival curves in rectal patients according to four subgroups

The 5-year cancer specific survival was 52.1% in surgery only, 27.7% in RT only, 70.4% in neoadjuvant RT and 60.4% in adjuvant RT, which had significant difference in univariate log-rank test (P < 0.001) and multivariate Cox regression (P < 0.001).

Table 2

Univariate and multivariate survival analyses of rectal cancer patients according to various clinicopathological variables

Variablen5-year CSS (%)UnivariateMultivariate
PP
Sex0.2240.601
 Male207758.6
 Female204456.9
Race0.2880.259
 White350457.2
 Black26557.6
 Other35263.9
Treatment pattern<0.001<0.001
 Surgery only146052.1
 RT only57727.7
 Neoadjuvant RT149870.4
 Adjuvant RT58660.4
Histological Type0.0220.013
Adenocarcinoma384758
 Mucinous /Signet ring cell27453.2

Survival curves in rectal patients according to four subgroups

The 5-year cancer specific survival was 52.1% in surgery only, 27.7% in RT only, 70.4% in neoadjuvant RT and 60.4% in adjuvant RT, which had significant difference in univariate log-rank test (P < 0.001) and multivariate Cox regression (P < 0.001).

DISCUSSION

The incidence of rectal cancer is highest in elderly patients. However, patients aged 75 years and older are often underrepresented in randomized studies. Therefore, it is not clear whether results of rectal cancer studies are equally applicable to elderly patients. Ideally, randomized studies for elderly patients should be performed. Extrapolation of results of younger patients may not be appropriate. In our study, we found elderly patients in neoadjuvant RT had the best CSS. Higher rates of surgical complications, more prevalent co-morbidities, and poorer performance status limit the standard use of multidisciplinary treatment in older patients, and treatment deviation is higher in elderly patients than younger patients. A Surveillance, Epidemiology, and End Results (SEER)-Medicare study of patients more than 65 years of age who were receiving postoperative therapy for rectal cancer showed that 96.6% of Stage III rectal cancer patients completed radiation therapy, only 68.2% and 67.5% completed chemotherapy and both modalities. Among Stage II cancer patients, 91.5% completed radiation therapy but only 49.8% and 47.6% completed chemotherapy both modalities [9]. The rates of treatment deviation may be even higher among individuals 75 years or older. Aparicio et al. found a standard cancer treatment according to recommendations was performed in 53 (48%) colorectal cancer patients: adjuvant chemotherapy in 6/23 patients with stage III tumour, palliative chemotherapy in 3/18 patients with stage IV tumour and adjuvant radiotherapy in 4/14 patients who had a rectal tumour resection [10]. Margalit et al. showed 92% rectal patients aged 75 years and older (33/36) completed the planned radiotherapy (RT) dose, 25% (9/36) required an RT-treatment break, 11% (4/36) were hospitalized, and 33% (12/36) had a dose reduction, break, or discontinuation of concurrent chemotherapy [11]. In contrast, Tougeron et al. found in selected elderly patients, chemoradiotherapy is well-tolerated, without any significant increase in adverse events, and the results are similar to those recorded in younger patients [12]. Cai et al. also suggested that although toxicities may be significant, elderly patients with rectal cancer of varied stages can be safely treated with RT or CRT with careful monitoring and frequent modification of treatment [13]. In the Dutch TME-study, patients aged 75 years and older showed a better response in the study arm when compared to younger patients. Younger patients have a significantly lower local recurrence rate of 5.2% after preoperative radiotherapy versus 11% for patients without preoperative radiotherapy (p = 0.001). However, overall survival at 5 years, distant metastases free survival and cancer-free survival were not improved. Whereas in the elderly, apart from local recurrence rate (5.4% versus 14%, p = 0.02), also distant metastases free survival (81% versus 69%, p = 0.07) and cancer-free survival (81% versus 66%, p = 0.03) were improved. Thus, the biological behavior of rectal cancer in the elderly in response to radiotherapy is better than in younger patients [14]. Moreover, no significant differences with respect to postoperative morbidity and mortality were found between neoadjuvant RT and surgery only [14-16]. Therefore, neoadjuvant RT and surgery may be the optimal treatment strategy in elderly patients, especially to patients medically fit for the operation. Surgery is more effective than radiation only. Thus, it is meaningful to optimize the condition of the patient; making him or her more fit for the operation. All colorectal operations carry significant associated risk. To facilitate the best outcomes it is essential to perform a comprehensive evaluation of patient risk preoperatively. Once risk factors are identified the appropriate steps must be taken to minimize their effects. The evaluation of the patient can be broken down by organ systems such as cardiac, pulmonary, hepatic, renal, and gastrointestinal. Additionally, one can assess whether the patient is at risk for infection, hyperglycemia, malnutrition, venous thromboembolism, and anemia. There are many preemptive steps that can be taken to improve patient outcomes in all of these categories. The ultimate goal is achieving improved outcomes [17-23]. Although this is a large population-based study, it has several potential limitations. First, the SEER registry does not collect comorbidity data. One reason that the elderly patients may be undergoing less aggressive treatment may be due to comorbidities. Second, our study is the lack of data in the SEER registry on the use of chemotherapy, resulting in a potentially significant confounder in the current study. It is possible that patients may have received adjuvant chemotherapy or preoperative chemotherapy. Because preoperative chemoradiation has been the standard of care for patients with locally advanced rectal cancer (LARC). As for patients who are older than 75 years of age, they may receive less chemotherapy. Finally, the current analysis of the nonrandomized patient population could not exclude the possibility of selection bias. One of the treatment patterns was chose for patients may according to their performance status and comorbidities. However, if patients are medically fit for surgery, they may benefit from neoadjuvant radiation. In conclusion, multimodal therapy is underused in elderly patients. It appears that standard treatment established in young patients is not applied to every elderly patient. However, the neoadjuvant RT and surgery may be the optimal treatment pattern in elderly patients, especially for patients who are medically fit for the operation.

MATERIALS AND METHODS

Patient selection in the SEER database

The SEER, a population-based reporting system, was surveyed for the retrospective collection of data used in the analysis. The SEER program collects and publishes cancer incidence and survival data from 18 population-based cancer registries, covering >25% of the US population. Because no personal identifying information was used in the analysis, this study was granted an exemption from the Institutional Review Board of the study institution on March 30, 2012. Cases of rectal cancer (C20.9 Rectum, NOS) from 2004 to 2011 were extracted from the SEER database (SEER*Stat 8.1.5) according to the Site Recode classifications with limitation to radiation prior to surgery and radiation preoperatively and post-surgery. Histological type were limited to adenocarcinoma (ICD-03, 8140/3, 8210/3, 8261/3, 8263/3), mucinous adenocarcinoma (ICD-03, 8480/3), and signet ring cell carcinoma (ICD-03, 8490/3). We selected this range because American Joint Committee on Cancer (AJCC) TMN stage was available since 2004. Other exclusion criteria were as follows: synchronous distance metastases and patients with unknown TNM stage.

Statistical analysis

Age, sex, race, histological grade, histotype and cancer specific survival (CSS) were extracted from SEER database. CSS was calculated from the date of diagnosis to the date of cancer specific death. Deaths attributed to the rectal cancer were treated as events and deaths from other causes were treated as censored observations. The Kaplan-Meier method was used to estimate the CSS [6]. The association between each of the potential prognostic factors and the estimated CSS was tested with the log-rank test [7]. Multivariate analysis was performed using the Cox regression model [8]. The statistical test was two sided and P < 0.05 was considered statistically significant. PASW Statistics 13 (SPSS Inc., Chicago, USA) was used for the statistical analysis.
  22 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Multistate life-tables and regression models.

Authors:  R D Gill
Journal:  Math Popul Stud       Date:  1992       Impact factor: 0.720

3.  Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres.

Authors:  David Tougeron; Bernard Roullet; Bernard Paillot; Hadji Hamidou; Jean-Marc Tourani; Réné-Jean Bensadoun; Pierre Michel; Christine Silvain
Journal:  Dig Liver Dis       Date:  2011-11-25       Impact factor: 4.088

4.  Preoperative evaluation and risk management.

Authors:  David P Parsons
Journal:  Clin Colon Rectal Surg       Date:  2009-02

5.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

6.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.

Authors:  Willem van Gijn; Corrie A M Marijnen; Iris D Nagtegaal; Elma Meershoek-Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm J T Rutten; Lars Påhlman; Bengt Glimelius; Cornelis J H van de Velde
Journal:  Lancet Oncol       Date:  2011-05-17       Impact factor: 41.316

7.  The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer.

Authors:  C H Richards; E F Leitch; P G Horgan; J H Anderson; R F McKee; D C McMillan
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

8.  Validation of risk assessment scoring systems for an audit of elective surgery for gastrointestinal cancer in elderly patients: an audit.

Authors:  Hisao Wakabayashi; Takanori Sano; Shinichi Yachida; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki
Journal:  Int J Surg       Date:  2007-03-18       Impact factor: 6.071

9.  Postoperative 30-day mortality in patients undergoing surgery for colorectal cancer: development of a prognostic model using administrative claims data.

Authors:  S de Vries; D B Jeffe; N O Davidson; A D Deshpande; M Schootman
Journal:  Cancer Causes Control       Date:  2014-08-08       Impact factor: 2.506

10.  Predictive value of POSSUM and ACPGBI scoring in mortality and morbidity of colorectal resection: a case-control study.

Authors:  Pascal H E Teeuwen; A J A Bremers; J M M Groenewoud; C J H M van Laarhoven; R P Bleichrodt
Journal:  J Gastrointest Surg       Date:  2010-10-09       Impact factor: 3.452

View more
  3 in total

Review 1.  Management of locally advanced rectal cancer in the elderly: a critical review and algorithm.

Authors:  Lara Hathout; Nell Maloney-Patel; Usha Malhotra; Shang-Jui Wang; Sita Chokhavatia; Ishita Dalal; Elizabeth Poplin; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2018-04

2.  The impacts of surgery of the primary cancer and radiotherapy on the survival of patients with metastatic rectal cancer.

Authors:  Duo Tong; Fei Liu; Wenhua Li; Wen Zhang
Journal:  Oncotarget       Date:  2017-07-11

3.  Short-Course Radiotherapy in Locally Advanced Rectal Cancer.

Authors:  Maria Cambray; Javier Gonzalez-Viguera; Miguel Angel Berenguer; Miquel Macià; Ferran Losa; Gemma Soler; Ricard Frago; J Castellví; E Guinó
Journal:  Clin Transl Gastroenterol       Date:  2020-06       Impact factor: 4.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.